## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.43 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.3% MRS), overbought RSI (79).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($81.65)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Solventum Corporation (NYSE:SOLV) Surges 26% Yet Its Low P/E Is No Reason For Excitement**
- Source: Simply Wall Street | 20251205T111807 | Somewhat-Bearish | Relevance: 100%
- Solventum Corporation has seen a 26% surge in its stock price over the last month and a 22% rise over the past year. Despite this, its low Price-to-Earnings (P/E) ratio of 9.7x, significantly lower than the US market average, suggests that investors anticipate future earnings declines. Analysts forecast a 48% drop in earnings over the next year for Solventum, which explains the low P/E compared to a market expecting 16% growth.

**2. Solventum Corporation (SOLV) Stock Price | Live Quotes & Charts | NYSE**
- Source: StocksToTrade | 20251204T002223 | Neutral | Relevance: 100%
- This article provides live stock quotes and charts for Solventum Corporation (SOLV), showing its current stock price and daily change. It also presents analyst ratings, though none are available, and notes the absence of earnings information. The page includes prompts for users to discover popular stocks and sign up for trade alerts.

**3. Korea Investment CORP Grows Holdings in Solventum Corporation $SOLV**
- Source: MarketBeat | 20251204T071256 | Bullish | Relevance: 100%
- Korea Investment CORP significantly increased its stake in Solventum Corporation ($SOLV) by 46.2% in Q2, acquiring 28,726 shares to hold a total of 90,933 shares valued at approximately $6.90 million. Solventum itself has authorized a $1.0 billion share repurchase program, covering up to 7.5% of its outstanding stock, and surpassed quarterly earnings expectations with $1.50 EPS on $2.10 billion revenue, setting FY2025 guidance at $5.98-$6.08 EPS. The stock holds a "Hold" consensus rating with a target price of $85.56 from MarketBeat analysts.

**4. (SOLV) Volatility Zones as Tactical Triggers**
- Source: Stock Traders Daily | 20251203T211000 | Neutral | Relevance: 100%
- This article provides a detailed AI-driven analysis for Solventum Corporation (NASDAQ: SOLV), highlighting neutral near-term readings and potentially stalling mid-term strong sentiment. It outlines three distinct institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for support and resistance levels.

**5. BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing**
- Source: TradingView | 20251205T170803 | Somewhat-Bullish | Relevance: 73%
- Becton, Dickinson and Company (BDX) has announced a collaboration with ChemoGLO to enhance hazardous drug contamination testing in healthcare settings, aiming to improve worker safety. This partnership is expected to boost BD's MDS business unit and capitalize on the growing global drug screening market. Following the announcement, BD's stock saw a slight gain, with market sentiment anticipated to remain positive.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |
| 2025-11-10 | UBS | $79 | $77 | +3% |
| 2025-11-07 | Piper Sandler | $98 | $94 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |
| 2025-11-10 | UBS | main | Neutral |
| 2025-11-07 | Piper Sandler | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.43 suggests fair value with growth premium. Forward P/E 13.4x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.43 |
| Forward P/E | 13.4 |
| Current P/E | 14.2 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 10.5% to 4.3% (-6.3% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 81st percentile. MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.7% shows strong absolute momentum above own 20MA. Outperforming sector by 6.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 79, risk of mean reversion. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.27% (CS: 82) | Strong |
| RSI_14 | 79.1 | Overbought |
| MACD Histogram | 0.40 | Bullish |
| vs SMA20 | 1.067x | Above |
| vs SMA50 | 1.142x | Above |
| vs SMA200 | 1.164x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $85.43
- **Stop Loss:** $81.65 (4.4% risk)
- **Target:** $92.99 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $11,276.76
- **Portfolio %:** 11.28%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*